Mark Fendrick, MD, Discusses Value-Based Insurance Design
Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care. Dr. Fendrick discusses the importance of combining the supply side, or how you pay doctors, and the demand side of value, or consumer engagement. Dr. Fendrick also says that the goal of improved health and cost containment can be achieved when the two sides are combined.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.
Budget cuts mean county health clinics will be unable to fill hundreds of jobs, leaving smaller staffs to serve low-income people in state that declined to expand Medicaid despite pleas from its hospitals and business leaders.
Emergency care providers vary in their understanding of a type of medical order intended to communicate seriously ill patients' choices for life-sustaining treatments, according to a pair of studies recently published.
The American Journal of Managed Care convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA’s plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.
Evidence-Based Oncology, an indexed publication of The American Journal of Managed Care, devotes its current issue to immuno-oncology and the interests of many stakeholders. In a commentary that draws on 30 years of waiting on the promise of immuno-oncology, Bruce Feinberg, DO, outlines the key issues facing payers, oncologists, policymakers and patients themselves.